Analysts: Abercrombie’s Set-Up Is ‘Favorable’ and 3 More Research Notes to Look Over
Abercrombie & Fitch Co. (NYSE:ANF): Piper Jaffray believes that the set-up for Abercrombie & Fitch into Wednesday’s strategic update event is favorable, with the negative pre-announcement now out of the way; the firm has lowered its price target for shares to $43 from $44, though it keeps an Overweight rating on Abercrombie & Fitch stock.
Lululemon Athletica (NASDAQ:LULU): Citigroup does not believe Lululemon’s Groove Pant is transparent when worn, after “trying on multiple pairs,” and believes that pilling only occurs under select circumstances. The firm further notes that problems with the pant are isolated and does not expect Lululemon’s guidance to be affected by the issues; it keeps a Buy rating on the stock, with an $80 price target.
Jazz Pharmaceuticals (NASDAQ:JAZZ): Citigroup has raised its price target for Jazz Pharmaceuticals to $107 from $93 after the company’s third-quarter report and keeps a Buy rating on the stock as it states that it remains confident in positive results from the Xyrem patent challenges and continues to view Jazz Pharmaceuticals as an attractive opportunity.
Hain Celestial (NASDAQ:HAIN): Jefferies has increased its price target for Hain Celestial shares to $96 from $91 following the company’s first-quarter results. The firm, which keeps a Buy rating on the stock, says that strong growth in the U.S. is helping to offset the weaker-than-expected gains for Hain Celestial in the U.K.